E137: Inflation cools, market rips, Ripple/MSFT beat regulators, NATO summit, cocktails of youth

Markets can rally even with higher-for-longer interest rates if sentiment turns.

Chamath argues that once investors believe the worst is behind them, trillions parked in defensive assets will rotate into equities, and by the time consensus recognizes the shift, much of the upside will already be gone.

Short-term cost-cutting is not a durable substitute for real innovation.

Big tech stocks bounced largely because they stopped wasteful spending, but the hosts stress that long-term value will accrue to companies with genuine product–market fit and usage-driven growth, not just austerity.

Rising credit costs are beginning to bite consumers and autos in particular.

With auto loan rates roughly doubling and most new cars financed, used car prices and EV demand outside Tesla are softening, suggesting early signs of consumer strain even as headline economic data looks resilient.

Ripple’s court win sharply weakens the SEC’s “everything is a security” stance.

A judge ruled XRP sales on public exchanges were not securities transactions, which the hosts see as a major precedent that undermines the SEC’s aggressive crypto posture and likely emboldens other token issuers to fight rather than settle.

FTC’s aggressive, scattershot antitrust strategy is backfiring in court.

Lina Khan’s repeated losses, including on Microsoft–Activision, are portrayed as ideologically driven and poorly targeted, weakening institutional credibility and missing more obvious anticompetitive issues like bundling, app-store lock-in, and dark patterns.

NATO expansion brings security guarantees but also greater U.S. liabilities.

Sacks argues that adding countries like Finland and Sweden expands the military-industrial complex’s customer base but also extends America’s defense obligations and heightens direct confrontation risks with nuclear-armed Russia.

Small-molecule “youth cocktails” could make age reversal therapeutically practical.

Friedberg highlights new research identifying small-molecule combinations that mimic Yamanaka-factor rejuvenation without gene therapy, potentially enabling pills or topicals that reverse cellular aging and transform longevity medicine.